Status:

TERMINATED

Predicting the Success of Dry Eye Disease Interventions Using Clinical Tests

Lead Sponsor:

Tufts Medical Center

Conditions:

Dry Eye

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

This is a single site, prospective, cross-sectional, controlled clinical study on a total of 66 subjects. The subjects are divided into two groups: Hypertonic Saline Non-Responders (33 subjects) and H...

Eligibility Criteria

Inclusion

  • Group 1 (Hypertonic saline non-responders):
  • At least 18 years of age
  • Ability to consent
  • Diagnosis of Dry Eye Disease (DED) based on:
  • Symptoms of DED, shown with SANDE score of 50mm or greater
  • Two or more of the following objective signs in the same eye: 1. Schirmer test of 10 mm or less over 5 minutes; 2. Fluorescein tear break-up time (FTBUT) of 7 seconds or less; 3. Meibomian gland expression (MGE) grade of 2 or greater for at least 3 out of 5 glands
  • HS response result of one of the following:
  • Reduction of discomfort/pain rating
  • No change of discomfort/pain rating
  • Increase in discomfort/pain rating score of 1 step or less
  • Group 2 (Hypertonic saline non-responders):
  • At least 18 years of age
  • Ability to consent
  • Diagnosis of DED based on:
  • Symptoms of DED, shown with SANDE score 50mm or greater
  • Two or more of the following objective signs in the same eye: 1. Schirmer test of 10 mm or less over 5 minutes; 2. Fluorescein tear break-up time (FTBUT) of 7 seconds or less; 3. Meibomian gland expression (MGE) grade of 2 or greater for at least 3 out of 5 glands
  • HS response result of an increase in discomfort/pain rating of greater than 1 step

Exclusion

  • Presence of centralized pain as indicated by a proparacaine challenge test (PCT) of less than 50% ocular surface discomfort reduction
  • Unable to speak English
  • History of ocular surgery, corneal infection, or corneal injury within the last 3 months
  • Active ocular allergies or other condition that could impact the study results
  • Allergic to benzalkonium chloride "BAK" (an eye-drop preservative)
  • Changes in topical or systemic medications in the last 3 months or anticipated changes in medication during the course of treatment
  • Use of other topical treatments
  • Concurrent enrollment in other studies that in the opinion of the investigator will interfere with the results of this study
  • Use of contact lenses within the last month

Key Trial Info

Start Date :

October 3 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 31 2025

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT04125134

Start Date

October 3 2019

End Date

July 31 2025

Last Update

September 22 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Tufts Medical Center-New England Eye Center

Boston, Massachusetts, United States, 02111

Predicting the Success of Dry Eye Disease Interventions Using Clinical Tests | DecenTrialz